TandemAI operates a fully integrated drug discovery engine that blends generative AI, molecular dynamics, quantum-mechanics simulations, and an AI-powered SaaS platform called TandemViz with expansive chemistry and biology laboratories. This computation-first approach spans target prediction through clinical candidate nomination and has already produced more than ten high-value drug candidates now in or approaching clinical trials. The company serves a network of over 150 global pharmaceutical partners, helping advance more than 50 innovative pipelines and achieving 10× revenue growth since launch. A recent merger with Perpetual Medicines added deep expertise in peptide and antibody-peptide conjugate discovery, broadening TandemAI’s modality coverage. The firm employs more than 300 professionals and maintains R&D hubs in New York, Boston, and China. Founded in October 2021, TandemAI has raised more than $80 million to date to scale its AI models, wet-lab capacity, and commercial reach.

Total raised

$82M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2025